DYNAVAX TECHNOLOGIES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.21 USD | +0.36% |
|
-5.00% | -19.81% |
| 04-01 | Dynavax Technologies Corporation Announces Chief Financial Officer Changes | CI |
| 02-23 | Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue | MT |
| Sales 2024 * | 288M 394M | Sales 2025 * | 347M 474M | Capitalization | 1.47B 2.01B |
|---|---|---|---|---|---|
| Net income 2024 * | 27M 36.91M | Net income 2025 * | 51M 69.71M | EV / Sales 2024 * | 3.1 x |
| Net cash position 2024 * | 576M 787M | Net cash position 2025 * | 711M 971M | EV / Sales 2025 * | 2.18 x |
| P/E ratio 2024 * |
48.7
x | P/E ratio 2025 * |
31.1
x | Employees | 408 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.69% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dynavax Technologies Corporation
More recommendations
More press releases
More news
| 1 day | +0.36% | ||
| 1 week | -5.00% | ||
| Current month | -9.67% | ||
| 1 month | -9.67% | ||
| 3 months | -15.84% | ||
| 6 months | -21.22% | ||
| Current year | -19.81% |
1 week
11.03
12.08
1 month
11.0312.67
Current year
11.0315.01
1 year
10.0615.15
3 years
7.0921.39
5 years
1.8021.39
10 years
1.8032.49
| Managers | Title | Age | Since |
|---|---|---|---|
Ryan Spencer
CEO | Chief Executive Officer | 46 | 04-12-31 |
David Novack
PSD | President | 62 | 13-03-24 |
Patricia Novy
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Francis Cano
BRD | Director/Board Member | 79 | 09-11-02 |
Peggy Phillips
BRD | Director/Board Member | 70 | 06-07-31 |
Dan Kisner
BRD | Director/Board Member | 77 | 10-07-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.28% | 27 M€ | -5.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 11.21 | +0.36% | 1,876,264 |
| 24-04-25 | 11.17 | -2.19% | 1,920,552 |
| 24-04-24 | 11.42 | -2.89% | 1,455,029 |
| 24-04-23 | 11.76 | -0.68% | 1,443,813 |
| 24-04-22 | 11.84 | +0.34% | 2,575,881 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.21
USD
Average target price
24.67
USD
Spread / Average Target
+120.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.81% | 1.47B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- DVAX Stock
